We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

58 hedge funds and large institutions have $23.7M invested in IVERIC bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $22.6M → $23.7M (+$1.13M)

8% less funds holding

Funds holding: 6358 (-5)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
58
Holders Change
-5
Holders Change %
-7.94%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
6
Increased
17
Reduced
20
Closed
11
Calls
Puts
Net Calls
Net Calls Change

ISEE Hedge Fund Activity: Q1 2019 in Review

58 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q1 2019, worth a combined $23.7M — up 5% from $22.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ISEE and 6 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was Tamarack Advisers, adding an estimated $2.8M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.57M.

  • 58 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q1 2019, down from 63 in Q4 2018.
  • Funds reported $23.7M of IVERIC bio, Inc. Common Stock stock for Q1 2019, up 5% quarter-over-quarter.
  • 6 funds opened new IVERIC bio, Inc. Common Stock positions in Q1 2019 and 11 closed out, a net change of -5 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q1 2019 was Tamarack Advisers, an estimated $2.8M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q1 2019 was D.E. Shaw & Co, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2019.